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Abstract Environmental factor(s), such as viral infection, has
been implicated as one of the triggering events leading to neuro-
in£ammation in multiple sclerosis. This study underlines the
importance of double-stranded RNA (dsRNA), the active com-
ponent of a viral infection, in inducing the expression of induc-
ible nitric oxide synthase (iNOS) in human astroglia. DsRNA in
the form of synthetic polyinosinic-polycytidylic acid (poly IC)
induced expression of iNOS and iNOS promoter-driven lucifer-
ase activity through activation of nuclear factor (NF)-UB and
CCAAT/enhancer-binding proteinL (C/EBPL). In addition, we
show that inhibitors of protein kinase R attenuated iNOS by
suppressing the activation of NF-UB but not C/EBPL. In con-
trast, knock down of p38 mitogen-activated protein kinase
(MAPK) attenuated iNOS by suppressing the activation of
C/EBPL but not NF-UB. This study delineates a novel role of
dsRNA in inducing the expression of iNOS through dsRNA-
activated protein kinase (PKR)-mediated activation of NF-UB
and p38-mediated activation of C/EBPL in human astroglia that
may participate in virus-induced neurological abnormalities.
0 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Multiple sclerosis (MS) is an autoimmune, in£ammatory,
demyelinating disease of the central nervous system (CNS)
that generally a¥icts persons between the ages of 20 and 50
years. The major pathological hallmark of MS is the presence
of sclerotic plaques in the CNS which are characterized by
demyelination associated with a broad-spectrum in£ammatory
reaction orchestrated by activated lymphocytes, macrophages,
and endogenous glial cells (astroglia and microglia) [1].
Although the etiology of MS remains unknown, epidemiolog-
ical studies suggest that both environmental and genetic fac-
tors play a role [1,2]. Environmental factor(s), particularly
viral infection, has been implicated as one of the potential
triggering events leading to demyelination in MS [2,3]. De-
myelination in both humans and rodents can be initiated by
infection with a diverse group of viruses. Consistently, both
retroviral expression and cytotoxic factor production have
been evidenced in MS monocyte/macrophage cultures and
MS cerebrospinal £uid. Furthermore, human coronaviruses
(HCoV), which cause common colds, can also infect neural
cell cultures [4,5]. Coronaviruses induce an MS-like disease in
rodents, and are neuroinvasive in humans [6,7]. Consistently,
HCoV RNA was detected in MS patient brains [6,8] and in
cerebrospinal £uid of MS and other neurological disease pa-
tients [7]. Coronavirus antigens were also detected in MS pa-
tient brains [8]. It is possible that a viral infection acquired
during adolescence initiates MS after a long period of quies-
cence. However, the mechanism by which viral infection leads
to neuroin£ammation and demyelination in MS is poorly
understood.
The active component of a viral infection that stimulates
antiviral activities appears to be double-stranded RNA
(dsRNA), which accumulates during the replication of many
viruses [9]. Nitric oxide (NO) produced from the expression of
inducible nitric oxide synthase (iNOS) participates in the
pathogenesis of MS [10,11]. We herein report that dsRNA
markedly induces the expression of iNOS in human astroglia.
2. Materials and methods
2.1. Reagents
Poly IC was obtained from Sigma. The dominant-negative mutants
of CCAAT/enhancer-binding proteinL (vC/EBPL), p38 (vp38) and
dsRNA-activated protein kinase (PKR) (vPKR) were kindly provided
by Dr. S. Smale of the University of California at Los Angeles, Dr. J.
Alam of Alton Ochsner Medical Foundation at New Orleans, and Dr.
R. Donis of the University of Nebraska at Lincoln, respectively. The
pMT-K3L was obtained from Dr. B. L. Jacobs, Arizona State Uni-
versity at Tempe.
2.2. Astrocytes
Human primary astrocytes were prepared as described earlier
[12,13]. Human U373MG astroglial cells were obtained from Ameri-
can Type Culture Collection (ATCC).
2.3. Assay for NO synthesis
Culture supernatants were assayed for nitrite, a stable reaction
product of NO with molecular oxygen, using Griess reagent [12,13].
2.4. Immunoblot analysis for iNOS
Immunoblot analysis for iNOS was carried out as described earlier
[12,13] using antibodies against mouse macrophage iNOS.
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2.5. RNA isolation and Northern blot analysis
Northern blot analysis for iNOS mRNA expression was carried out
as described earlier [12,13] using 32P-labeled cDNA probe.
2.6. Assay of iNOS promoter-driven reporter activity
Human 7.2-kb iNOS promoter-driven luciferase activity was moni-
tored as described earlier [12,13] using phiNOS(7.2)Luc. Brie£y, 24 h
after transfection, cells were treated with stimuli for 12 h. Fire£y and
Renilla luciferase activities were obtained by analyzing total cell ex-
tract according to standard instructions provided in the Dual Lucif-
erase Kit (Promega) in a TD-20/20 luminometer (Turner Designs).
2.7. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared and used for EMSA using 32P end-
labeled double-stranded nuclear factor (NF)-UB, 5P-AGT TGA GGG
GAC TTT CCC AGG C-3P and C/EBP, 5P-TGC AGA TTG CGC
AAT CTG CA-3P oligonucleotides as described earlier [14]. Double-
stranded mutated NF-UB, 5P-AGT TGA GGC GAC TTT CCC AGG
C-3P, and C/EBP, 5P-TGC AGA GAC TAG TCT CTG CA-3P (Santa
Cruz Biotechnology, Inc.) oligonucleotides were used to verify the
speci¢city of binding. For supershift analysis, 1 Wg of antibodies
against C/EBPL (Santa Cruz Biotechnology, Inc.) were included in
the binding reaction.
2.8. Assay of transcriptional activities of NF-UB and C/EBPL
Transcriptional activities of NF-UB and C/EBPL were assayed as
described earlier [12^14] using pNF-UB-Luc (an NF-UB-dependent
reporter construct) or pC/EBPL-Luc (an C/EBPL-dependent reporter
construct).
3. Results
3.1. Poly IC induces the production of NO and the expression
of iNOS in human U373MG astroglial cells and primary
astroglia
Poly IC, a synthetic dsRNA copolymer of inosinic and
cytidylic acids, has been often used as a tool to mimic the
e¡ects of dsRNA intermediates produced during viral infec-
tion of cells [9]. It is evident from Table 1 that poly IC alone
markedly induced the production of NO in U373MG astro-
glial cells. Since poly IC is made up of two homopolymers of
inosinic and cytidylic acids, we examined if each of these
polymers could induce NO. In contrast to dsRNA, treatment
of U373MG astroglial cells with single-stranded RNA
(ssRNA) (either poly I or poly C) resulted in very little in-
duction of NO production (Table 1) suggesting that the pres-
ence of RNA with double-stranded structures is required for
the induction of NO. Furthermore, these results also sug-
gested that the induction of NO production was not due to
lipopolysaccharide (LPS) contamination in the RNA prepara-
tion, which is a potent inducer of NO production in di¡erent
cells. The inhibition of poly IC-induced production of NO by
arginase (an enzyme that degrades the substrate, L-arginine, of
NOS) and L-NMMA (a competitive inhibitor of NOS) but not
by D-NMMA (a negative control of L-NMMA) suggests that
poly IC induces the production of NO through NOS-mediated
arginine metabolism (Table 1). To understand the mechanism
of induction of NO production, we examined the e¡ect of
poly IC on protein and mRNA levels of iNOS. Fig. 1 shows
that poly IC dose dependently induced the production of NO
(A) and the expression of iNOS protein (B) and mRNA (C).
Similarly poly IC also induced iNOS promoter-driven lucifer-
ase activity in a dose-dependent fashion, and the maximum
induction of about 3.7-fold was observed at 100 or 150 Wg/ml
of poly IC (Fig. 1D). Consistent to the induction of iNOS in
U373MG astroglial cells, poly IC also dose dependently in-
Table 1
Poly IC induces the production of NO through NOS in human
U373MG astroglial cells
Treatments Nitrite (Wg/mg protein/24 h)
Control 6.2O 0.8
Poly IC (100 Wg/ml) 156.2O 19.7
Poly I (100 Wg/ml) 9.5O 1.8
Poly C (100 Wg/ml) 10.2O 1.5
Poly IC+arginase 7.4O 1.0
Poly IC+L-NMMA 17.4O 1.5
Poly IC+D-NMMA 154.9O 20.2
Cells were cultured for 24 h in serum-free Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM)/F-12 with the listed reagents; and nitrite
concentration in the supernatants was measured. Arginase (100
units/ml), L-NMMA (0.1 mM) and D-NMMA (0.1 mM) were added
to the cells together with poly IC. Data are meansOS.D. of three
di¡erent experiments.
Fig. 1. Dose-dependent induction of iNOS by poly IC in human as-
trocytes. U373MG astroglial cells were stimulated with di¡erent
concentrations of poly IC under serum-free condition. A: After 24 h,
supernatants were used for nitrite assay. B: Cell homogenates were
immunoblotted with antibodies against mouse macrophage iNOS.
C: After 6 h of incubation, Northern blot analysis for iNOS
mRNA was carried out. Human iNOS promoter-driven luciferase
activity was assayed in U373MG astroglial cells (D) and primary
astrocytes (E) as described in Section 2. Data are meansOS.D. of
three di¡erent experiments.
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duced the production of NO (data not shown) and iNOS
promoter-driven luciferase activity (Fig. 1E) in human pri-
mary astrocytes.
3.2. Involvement of NF-UB and C/EBPL in poly IC-induced
activation of iNOS promoter in human U373MG astroglial
cells
Recent evidences that activation of both NF-UB and C/
EBPL plays a role in the expression of iNOS [12^15]
prompted us to ask whether these two transcription factors
may be responsible for poly IC-induced expression of iNOS.
Stimulation of cells with poly IC led to the induction of
DNA-binding activity of NF-UB at di¡erent minutes of stim-
ulation (Fig. 2A). This gel shift assay detected a speci¢c in-
duced band (the upper band) in response to poly IC that was
not found either in unstimulated control cells or in case of
mutated double-stranded oligonucleotides. Consistent to the
e¡ect of poly IC on the DNA-binding activity of NF-UB, poly
IC induced NF-UB-dependent transcription of luciferase (Fig.
2B).
Similar to the activation of NF-UB, poly IC also induced
the DNA-binding activity of C/EBP at di¡erent minutes of
stimulation (Fig. 3A). However, this gel shift assay detected
two induced bands (the upper and the middle bands) in re-
sponse to poly IC that were not found either in unstimulated
control cells (Fig. 3A) or in case of mutated double-stranded
oligonucleotides (Fig. 3B). Since C/EBPL plays an important
role in the activation of iNOS promoter [12^14], we examined
if C/EBPL is induced by poly IC. Supershift analysis using
polyclonal antibodies against C/EBPL (Santa Cruz Biotech-
nology, Inc.) showed that the intensity of the upper band
but not of the middle one markedly reduced by anti-C/
EBPL antibodies (Fig. 3C). In contrast, non-speci¢c antibod-
ies had no e¡ect on DNA-binding activities (Fig. 3C) suggest-
ing that poly IC is able to induce the DNA-binding activity of
C/EBPL. Consistently, poly IC also induced the transcription-
al activity of C/EBPL (Fig. 3D).
Next we examined if activation of both NF-UB and C/EBPL
is important for poly IC-induced expression of iNOS. Over-
expression of dominant-negative molecules provides an e¡ec-
tive tool with which to investigate the in vivo functions of
di¡erent transcription factors or signaling molecules. There-
fore, NF-UB was inhibited by vp65, a dominant-negative mu-
tant of p65, and C/EBPL was inhibited by vC/EBPL [12,14].
Attenuation of iNOS promoter-driven luciferase activity by
either vp65 or vC/EBPL but not by an empty vector in
poly IC-stimulated cells (data not shown) suggests that the
activation of both NF-UB and C/EBPL is necessary for poly
IC-induced expression of iNOS in astroglial cells.
3.3. Role of PKR and p38 mitogen-activated protein kinase
(p38) in poly IC-induced activation of iNOS promoter in
U373MG astroglial cells
Next we investigated mechanisms by which poly IC couples
to NF-UB and C/EBPL for the expression of iNOS. Several
studies, e.g. [16], have shown that PKR plays an important
role in biological activities of poly IC. To investigate if PKR
is involved in poly IC-induced activation of human iNOS
promoter, we inhibited the function of PKR by vPKR. It is
evident from Fig. 4A that expression of the vPKR but not the
empty vector signi¢cantly inhibited (P6 0.01) poly IC-in-
duced activation of iNOS promoter. Interestingly, transcrip-
tional activity of NF-UB (Fig. 4B) but not of C/EBPL (Fig.
4C) was inhibited by vPKR. Vaccinia viral protein, K3L,
inhibits PKR [17]. Similar to vPKR, pMT-K3L also attenu-
ated the transcription of iNOS promoter (Fig. 5A) by sup-
pressing the activation of NF-UB (Fig. 5B) but not of C/EBPL
(Fig. 5C). These studies suggest that vPKR inhibits the ex-
pression of iNOS by suppressing the activation of NF-UB but
not of C/EBPL.
Because p38 has been shown to be involved in cytokine-
mediated expression of iNOS [18], we investigated the possi-
bility if p38 plays a role in poly IC-mediated expression of
iNOS. We used vp38 to inhibit the function of p38. Similar to
the e¡ect of vPKR, vp38 also inhibited human iNOS pro-
moter-driven luciferase activity (P6 0.01) in poly IC-stimu-
lated cells (Fig. 4A). However, in contrast to vPKR, vp38
inhibited poly IC-induced activation of C/EBPL (Fig. 4C)
but not of NF-UB (Fig. 4B). Consistently, SB203580, a speci¢c
inhibitor of p38, also knocked down the activation of iNOS
promoter by inhibiting the activation of C/EBPL but not of
NF-UB in poly IC-stimulated cells (data not shown). These
results suggest that inhibition of p38 attenuates poly IC-in-
duced expression of iNOS by impairing the activation of C/
EBPL but not of NF-UB. Since vPKR and vp38 decreased
poly IC-induced activation of iNOS promoter by acting on
distinct transcription factors, we examined if these two dom-
Fig. 2. Activation of NF-UB in poly IC-treated U373MG astroglial
cells. A: After di¡erent minutes of stimulation with 100 Wg/ml of
poly IC under serum-free condition, nuclear proteins were examined
for EMSA. The upper arrow indicates the induced NF-UB band,
and the lower arrow indicates the unbound probe. B: Transcription-
al activity of NF-UB was assayed as described in Section 2.
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inant negatives exhibited any additive e¡ect. However, after
combining both forms of mutants during transient transfec-
tion, we were unable to achieve more than 40% inhibition
(data not shown), and the reason behind this lies in the lack
of achieving su⁄cient transfection e⁄ciency. Earlier, we have
shown that during successful transient transfection experi-
ments by Lipofectamine Plus, transfection e⁄ciency varies
from 33 to 44% [19].
4. Discussion
Several human demyelinating disorders have a known viral
etiology [20,21]. Although the association of a virus with MS
has not been con¢rmed, based on detection of virions, viral
nucleic acids, or viral proteins in CNS or the presence of
antiviral antibodies in serum and/or cerebrospinal £uid
(CSF), several viruses have been shown to be associated
with MS [6^8]. A common viral structure that is almost uni-
versally recognized by eukaryotic cells is dsRNA (s 100 bp).
dsRNA is not present during the normal life cycle of eukary-
otic cells; however, it is present in virally infected cells. How-
ever, the biological function of dsRNA within the CNS is
poorly understood. Several lines of evidence presented here
clearly support the conclusion that dsRNA is capable of in-
ducing the expression of iNOS in human astroglia. Earlier
studies have shown that dsRNA inhibits L-cell function and
induces islet damage by stimulating L-cell production of NO
[22]. Since the expression of iNOS within the CNS participates
in the pathogenesis of MS, our ¢ndings could help explain
why exacerbations of MS are often associated with a variety
of di¡erent viral infections.
The signaling events for the induction of iNOS are not
completely established so far. Proin£ammatory cytokines (tu-
mor necrosis factor (TNF)-K, interleukin (IL)-1L, or interfer-
on (IFN)-Q) and LPS bind to their respective receptors and
induce the expression of iNOS via NF-UB activation [12^15].
Human iNOS promoter also contains 15 nucleotide sequences
[23] that conform to the consensus C/EBP box
TKNNGYAAK. Recently we have found that vC/EBPL in-
hibits cytokine- or HIV-1 Tat-induced activation of human
iNOS promoter in human astroglial cells [12,13] suggesting
the involvement of C/EBPL in cytokine- or Tat-induced ex-
Fig. 3. Activation of C/EBPL in poly IC-treated U373MG astroglial cells. A: At di¡erent minutes of stimulation with 100 Wg/ml of poly IC,
cells were taken out for EMSA. B: Nuclear proteins were examined for EMSA using wild-type and mutated C/EBP probes. C: 1 Wg of anti-
bodies against C/EBPL or a non-speci¢c protein were included in the binding reaction for supershift analysis. The upper, middle and lower ar-
rows indicate the induced DNA-binding activity of C/EBPL, the induced DNA-binding activity of another C/EBP isoform and the unbound
probes respectively. D: Transcriptional activity of C/EBPL was assayed as described above.
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pression of iNOS. Results presented in this manuscript clearly
demonstrate that activation of both NF-UB and C/EBPL is
also essential for dsRNA-mediated expression of iNOS in hu-
man astroglial cells.
DsRNA-dependent protein kinase (PKR), a 68-kDa serine-
threonine kinase, plays a primary role in mediating the anti-
viral activities of infected cells [17]. It has been shown that
NF-UB activation in response to dsRNA appears to be depen-
dent on functional PKR and that dsRNA-induced NF-UB
activation is attenuated in mouse embryonic ¢broblasts iso-
lated from PKR-de¢cient mice [24]. Chu et al. [25] have
shown that PKR may mediate dsRNA-induced NF-UB nu-
clear localization by activating IKK [24]. In addition, a
Toll-like receptor (TLR) molecule (TLR3) has been reported
to recognize dsRNA and activate NF-UB via PKR [26]. Con-
sistently, we have found that inhibitors of PKR suppress
dsRNA-induced activation of NF-UB, and thereby inhibit
the activation of iNOS promoter in human astroglial cells.
Earlier, Maggi et al. [27] have shown that PKR is required
for dsRNA-induced expression of iNOS but not for activation
of NF-UB in macrophages. In contrast, Blair et al. [28] have
reported that PKR is not required for dsRNA-induced iNOS
expression or NF-UB activation by islets. However, our stud-
ies have shown that PKR is required for dsRNA-induced
expression of iNOS and activation of NF-UB in human astro-
glial cells. These discrepancies may be explained by the exis-
tence of di¡erent regulatory mechanisms in di¡erent cell types.
In addition to the activation of NF-UB, dsRNA also induced
the activation of C/EBPL that has been also found to be
necessary for dsRNA-induced expression of iNOS. However,
similar to the inhibition of NF-UB activation, vPKR and
Fig. 4. E¡ect of vPKR and vp38 on iNOS promoter-driven lucifer-
ase activity (A) and activation of NF-UB (B) and C/EBPL (C) in
poly IC-stimulated U373MG astroglial cells. A: Cells were cotrans-
fected with 0.5 Wg of phiNOS-Luc, 50 ng of pRL-TK and 0.5 Wg of
either vPKR, vp38 or empty vector (pcDNA3). After 24 h of trans-
fection, cells were stimulated with 100 Wg/ml of poly IC for 12 h.
Cells were cotransfected with 0.5 Wg of either vPKR, vp38 or empty
vector, 50 ng of pRL-TK and 0.5 Wg of either pNF-UB-Luc (B) or
pC/EBPL-Luc (C). After 24 h of transfection, cells were stimulated
with 100 Wg/ml of poly IC for 6 h. Fire£y and Renilla luciferase ac-
tivities were analyzed. *P6 0.01 versus empty vector-transfected
cells.
Fig. 5. E¡ect of pMT-K3L on iNOS promoter-driven luciferase ac-
tivity (A) and the activation of NF-UB (B) and C/EBPL (C) in poly
IC-stimulated U373MG astroglial cells. A: Cells were cotransfected
with 0.5 Wg of either pMT-K3L or empty vector (pMT), 0.5 Wg of
phiNOS-Luc and 50 ng of pRL-TK. After 24 h of transfection, cells
were stimulated with 100 Wg/ml of poly IC for 12 h. Cells were co-
transfected with 0.5 Wg of either pMT-K3L or empty vector, 50 ng
of pRL-TK and 0.5 Wg of either pNF-UB-Luc (B) or pC/EBPL-Luc
(C). After 24 h of transfection, cells were stimulated with 100 Wg/ml
of poly IC for 6 h. Fire£y and Renilla luciferase activities were ana-
lyzed. *P6 0.01 versus empty vector-transfected cells.
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pMT-K3L did not inhibit dsRNA-induced activation of C/
EBPL (Figs. 4 and 5). These studies suggest that PKR is
coupled to the transcription of iNOS via activation of NF-
UB but not that of C/EBPL.
The role of mitogen-activated protein kinase (MAPK) and
in particular p38 in modulating the expression of iNOS has
been investigated [18]. We have found that vp38 inhibited
poly IC-induced activation of human iNOS promoter. How-
ever, interestingly, vp38 inhibited dsRNA-induced activation
of C/EBPL but not of NF-UB. These studies suggest that p38
regulates dsRNA-induced expression of iNOS via C/EBPL but
not via NF-UB. Taken together, dsRNA-induced activation of
NF-UB and C/EBPL in human astroglial cells involves two
distinct signaling pathways. PKR is coupled to the activation
of NF-UB but not of C/EBPL while p38 is coupled to the
activation of C/EBPL but not of NF-UB for dsRNA-induced
expression of iNOS.
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